• About us
• Contact

Advertisement

Organisation › Details

Bristol Myers Squibb Co. (BMS) (NYSE: BMY)

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram. Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company. *

 

	Start	1989-10-04 merged
	Group	Bristol Myers Squibb (BMS) (Group)
	Industry	pharmaceutical
	Region	New York, NY
	Country	United States (USA)
	Street	430 East 29th Street 14th Floor
	City	10016 New York, NY
	Tel	+1-212-546-4000
		Address record changed: 2024-01-05
Basic data	Employees	H: 10,001 to 50,00 (2018-12-31)
	Currency	USD
	Annual sales	22,561,000,000 (revenue, total, consolidated (2018) 2018-12-31)
	Profit	4,947,000,000 (2018-12-31)
	Cash	6,911,000,000 (2018-12-31)
		* Document for »About Section«:
		Record changed: 2024-12-24

Advertisement

More documents for Bristol Myers Squibb (BMS) (Group)

• [1] ITM Isotope Technologies Munich SE. (6/20/24). "Press Release: ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth". Garching....
• [2] Evotec SE. (6/12/24). "Press Release: Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb". Hamburg....
• [3] VantAI. (2/13/24). "Press Release: VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence". New York, NY....
• [4] GlycoEra AG. (1/5/24). "Press Release: GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer". Newton, MA & Wädenswil....
• [5] Immatics N.V.. (7/24/23). "Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb". Tübingen & Houston, TX....
• [6] Evotec SE. (7/11/23). "Press Release: Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership". Hamburg....
• [7] Evotec SE. (5/12/23). "Press Release: Evotec Publishes Annual Report 2022 and Quarterly Statement for Q1 2023". Hamburg....
• [8] Tubulis GmbH. (4/20/23). "Press Release: Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients". Munich....
• [9] Evotec SE. (3/28/23). "Press Release: Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership". Hamburg....
• [10] ADC Therapeutics S.A.. (7/1/22). "Press Release: ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors". Lausanne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.